Floatz logo

Treosulfan

Blasts Under 5 Percent of Bone Marrow Nucleated Cells

Fred Hutchinson Cancer CenterSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Blasts Under 5 Percent of Bone Marrow Nucleated Cells cohort.

Asset / SponsorPhaseRating
Fludarabine
Fred Hutchinson Cancer Center
Phase 2BB
Tazobactam
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3BB
Vancomycin
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3BB
Piperacillin
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3BB
CYCLOSPORIN A
Fred Hutchinson Cancer Center
Phase 2B

View all 27 →

Same molecule, other indications

Treosulfan is also rated in:

myelodysplastic syndromeDormant
BB
Indicative ·
68 / 100
View asset →
Lymphoblastic Leukemia, Acute, Childhood;Dormant
BB
Indicative ·
66 / 100
View asset →
acute biphenotypic leukemiaDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →